Kura Oncology financials
$10.81+1.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9M | $18.3M | $17.3M | $20.8M | $15.3M | $14.1M | $53.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $20.6M | $18.0M | $17.3M | $20.8M | $15.3M | $14.1M | $53.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 98.8% | 98.6% | 99.7% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$73.0M | -$78.8M | -$86.3M | -$80.0M | -$72.7M | -$64.7M | -$22.5M | -$59.9M | -$56.4M | -$54.5M | -$46.8M | -$42.5M |
| Net income | -$68.3M | -$73.3M | -$81.0M | -$74.1M | -$66.1M | -$57.4M | -$19.2M | -$54.4M | -$50.8M | -$49.5M | -$42.8M | -$38.6M |
| Net margin | −327.3% | −401.5% | −467.2% | −357.2% | −432.5% | −407.1% | −35.7% | — | — | — | — | — |
| Diluted EPS | $-0.77 | $-0.83 | $-0.92 | $-0.85 | $-0.75 | $-0.66 | $-0.22 | $-0.63 | $-0.59 | $-0.59 | $-0.55 | $-0.50 |
| EBITDA | -$72.6M | -$78.5M | -$85.9M | -$79.8M | -$72.4M | -$64.5M | -$22.3M | -$59.7M | -$56.2M | -$54.2M | -$46.8M | -$42.3M |
| Operating cash flow | -$62.5M | -$85.9M | $117.3M | -$80.6M | -$28.8M | -$71.9M | $269.1M | -$43.4M | -$42.5M | -$48.8M | -$34.3M | -$29.0M |
| Free cash flow | -$63.2M | -$86.0M | $115.0M | -$83.2M | -$30.2M | -$72.2M | $268.8M | -$43.4M | -$42.5M | -$48.9M | -$34.3M | -$29.0M |
| Diluted shares | 88.9M | 88.6M | 88.1M | 87.6M | 87.6M | 87.4M | 87.2M | 87.0M | 86.6M | 83.9M | 77.5M | 77.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.2M | $39.1M | $149.1M | $95.3M | $81.9M | $51.3M |
| Short-term investments | $448.8M | $541.7M | $518.1M | $454.4M | $548.8M | $606.9M |
| Total debt | $9.8M | $9.7M | $9.7M | $9.7M | $9.6M | $9.6M |
| Total assets | $587.8M | $652.6M | $738.4M | $649.4M | $682.4M | $743.8M |
| Total liabilities | $539.4M | $544.7M | $564.2M | $406.8M | $376.9M | $379.4M |
| Shareholders' equity | $48.4M | $107.9M | $174.1M | $242.5M | $305.5M | $364.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology